[go: up one dir, main page]

MX2010005905A - Compuestos multi-objetivo activos en un receptor de ppar y cannabinoide. - Google Patents

Compuestos multi-objetivo activos en un receptor de ppar y cannabinoide.

Info

Publication number
MX2010005905A
MX2010005905A MX2010005905A MX2010005905A MX2010005905A MX 2010005905 A MX2010005905 A MX 2010005905A MX 2010005905 A MX2010005905 A MX 2010005905A MX 2010005905 A MX2010005905 A MX 2010005905A MX 2010005905 A MX2010005905 A MX 2010005905A
Authority
MX
Mexico
Prior art keywords
ppar
pharmacophore
cannabinoid
membered ring
cannabinoid receptor
Prior art date
Application number
MX2010005905A
Other languages
English (en)
Inventor
Pierre Desreumaux
Salvatore Bellinvia
Philippe Chavatte
Sergio Baroni
Original Assignee
Giuliani Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani Int Ltd filed Critical Giuliani Int Ltd
Publication of MX2010005905A publication Critical patent/MX2010005905A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Existe una necesidad de compuestos farmacéuticos que tienen actividad, de por lo menos uno de un PPAR y un receptor de cannabinoide. Así se proporcionan tales compuestos, en donde el compuesto comprende: un farmacóforo de PPAR y un farmacóforo de cannabinoide unidos juntos por un radical que comprende un anillo bicíclico fusionado que comprende un anillo de cinco miembros fusionado con un anillo de seis miembros o un anillo de seis miembros fusionado con un anillo de seis miembros; en donde el farmacóforo de cannabinoide comprende el anillo biciclico fusionado; y el farmacóforo de PPAR comprende una funcionalidad del ácido salicílico, ácido alcoxibencilacético o ácido alcoxifenilacético; y en donde el farmacóforo de PPAR se une al anillo bicíclico del farmacóforo de cannabinoide a través de un enlace que comprende un grupo funcional amina o amida.
MX2010005905A 2007-12-21 2008-12-22 Compuestos multi-objetivo activos en un receptor de ppar y cannabinoide. MX2010005905A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE20070928A IE20070928A1 (en) 2007-12-21 2007-12-21 Multi target ligands
PCT/EP2008/068205 WO2009080821A2 (en) 2007-12-21 2008-12-22 Receptor targeting ligands

Publications (1)

Publication Number Publication Date
MX2010005905A true MX2010005905A (es) 2010-10-05

Family

ID=40801618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005905A MX2010005905A (es) 2007-12-21 2008-12-22 Compuestos multi-objetivo activos en un receptor de ppar y cannabinoide.

Country Status (15)

Country Link
US (1) US20110039808A1 (es)
EP (1) EP2222287A2 (es)
JP (1) JP2011506581A (es)
KR (1) KR20100098375A (es)
CN (1) CN101878027B (es)
AU (1) AU2008339902A1 (es)
BR (1) BRPI0820568A2 (es)
CA (1) CA2704268A1 (es)
EA (1) EA201070540A1 (es)
IE (1) IE20070928A1 (es)
IL (1) IL205669A0 (es)
MX (1) MX2010005905A (es)
NZ (1) NZ585326A (es)
WO (1) WO2009080821A2 (es)
ZA (1) ZA201002954B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
EP2811993B1 (en) 2012-02-09 2019-10-09 Nogra Pharma Limited Methods of treating fibrosis
CN105683263B (zh) * 2013-10-29 2019-09-10 Sabic环球技术有限责任公司 玻璃纤维增强聚烯烃组合物
CN110696216A (zh) 2013-11-15 2020-01-17 Sabic环球技术有限责任公司 用于生产玻璃纤维-增强热塑性聚合物组合物的方法
CN106133003A (zh) 2014-03-31 2016-11-16 Sabic环球技术有限责任公司 制造低排放聚丙烯的方法
WO2016083327A1 (en) 2014-11-27 2016-06-02 Sabic Global Technologies B.V. Process for the manufacture of long glass fibre reinforced polypropylene compositions
US10486335B2 (en) 2014-12-08 2019-11-26 Sabic Global Technologies B.V. Process for the manufacture of glass fibre reinforced pellets
US20180127567A1 (en) 2015-04-29 2018-05-10 Sabic Global Technologies B.V. Mass transit vehicle component
CN107922694B (zh) 2015-06-12 2023-08-15 Sabic环球技术有限责任公司 用于制造低排放聚丙烯的方法
CN106924272B (zh) * 2015-12-31 2021-04-13 中国医学科学院药物研究所 水杨酸甲酯糖苷在制备预防和/或治疗系统性红斑狼疮及其并发症药物中的用途
US11435355B2 (en) * 2016-02-09 2022-09-06 Albert Einstein College Of Medicine Residue-based pharmacophore method for identifying cognate protein ligands
WO2018017573A1 (en) 2016-07-21 2018-01-25 Sabic Global Technologies B.V. Flame retardant glass-filled polypropylene compositions and articles formed from the same
US10995158B2 (en) 2016-12-12 2021-05-04 Sabic Global Technologies B.V. Process for manufacture of low emission heterophasic polypropylene
WO2018108936A1 (en) 2016-12-12 2018-06-21 Sabic Global Technologies B.V. Process for manufacture of low emission homopolymer or random polypropylene
WO2020048862A1 (en) 2018-09-05 2020-03-12 Sabic Global Technologies B.V. Bicycle frame
SI3921299T1 (sl) 2019-02-08 2025-03-31 Nogra Pharma Limited Postopek izdelave 3-(4'-aminofenil)-2-metoksipropionske kisline in njenih analogov in vmesnih proizvodov
US20220273805A1 (en) * 2019-06-24 2022-09-01 Diverse Biotech, Inc. Cannabinoid Conjugate Molecules
WO2020263975A1 (en) 2019-06-24 2020-12-30 Diverse Biotech, Inc. Beta-lactam-cannabinoid conjugate molecules
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用
WO2025120036A1 (en) 2023-12-08 2025-06-12 Sabic Global Technologies B.V. Glass fibre reinforced thermoplastic polymer composition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195582B1 (en) * 1985-03-14 1990-01-24 SMITH KLINE DAUELSBERG GmbH 5-aminosalicylic acid derivatives of non-steroidal antiinflammatory acids
DE3812755A1 (de) * 1988-04-16 1989-10-26 Merck Patent Gmbh Salicylsaeurederivate
US5502035A (en) * 1993-08-06 1996-03-26 Tap Holdings Inc. N-terminus modified analogs of LHRH
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US7098025B1 (en) * 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
IL146564A0 (en) * 1999-05-24 2002-07-25 Mitsubishi Pharma Corp Phenoxypropylamine derivatives and pharmaceutical compositions containing the same
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
CA2387138A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Cannabimimetic indole derivatives
JPWO2001085693A1 (ja) * 2000-05-11 2004-01-08 萬有製薬株式会社 Ｎ−アシルテトラヒドロイソキノリン誘導体
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2833949B1 (fr) * 2001-12-21 2005-08-05 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
WO2003061699A1 (en) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedies for allergic diseases
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
WO2003091213A1 (en) * 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
US20050101542A1 (en) * 2002-08-20 2005-05-12 Regents Of The University Of California Combination therapy for controlling appetites
AU2003303376A1 (en) * 2002-12-19 2004-07-22 University Of Massachusetts Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US20040198777A1 (en) * 2002-12-20 2004-10-07 Mitokor, Inc. Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto
EP1603858A2 (en) * 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
WO2004113331A1 (en) * 2003-06-20 2004-12-29 Galderma Research & Development, S.N.C. Novel compounds that modulate pparϝ type receptors, and use thereof in cosmetic or pharmaceutical compositions
US20070093476A1 (en) * 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
JP2005162657A (ja) * 2003-12-02 2005-06-23 Takeda Chem Ind Ltd カンナビノイド受容体調節剤
US20080146811A1 (en) * 2004-07-23 2008-06-19 Hongfeng Deng Compounds and Methods For Treatment of Thrombosis
AR050631A1 (es) * 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
CN1955175A (zh) * 2004-10-28 2007-05-02 中国医学科学院药物研究所 香豆素衍生物及其制法和其药物组合物与用途
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CN101291665A (zh) * 2005-10-18 2008-10-22 希格马托制药工业公司 作为β-淀粉状蛋白聚集抑制剂的萘基衍生物
AU2007204991A1 (en) * 2006-01-05 2007-07-19 Kinemed, Inc. Compositions and methods of treatment using modulators of motonueron diseases
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20080221161A1 (en) * 2007-02-09 2008-09-11 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease

Also Published As

Publication number Publication date
CN101878027A (zh) 2010-11-03
IE20070928A1 (en) 2009-09-30
WO2009080821A2 (en) 2009-07-02
US20110039808A1 (en) 2011-02-17
KR20100098375A (ko) 2010-09-06
NZ585326A (en) 2012-07-27
CN101878027B (zh) 2013-01-16
ZA201002954B (en) 2011-08-31
BRPI0820568A2 (pt) 2015-06-16
IL205669A0 (en) 2010-11-30
CA2704268A1 (en) 2009-07-02
WO2009080821A3 (en) 2010-01-14
EP2222287A2 (en) 2010-09-01
EA201070540A1 (ru) 2010-12-30
AU2008339902A1 (en) 2009-07-02
JP2011506581A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
MX2010005905A (es) Compuestos multi-objetivo activos en un receptor de ppar y cannabinoide.
WO2009037001A3 (en) Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
PE20141182A1 (es) Derivados fusionados de aminodihidrotiazina
DK1888541T3 (da) Benzo(d)isoxazol-3-yl-amin-forbindelser og anvendelse af disse som vanilloidreceptorligander
MX2010003259A (es) Ensayo de monitoreo de farmacos.
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
BR112014013974A2 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
EA201190179A1 (ru) Способы и промежуточные химические соединения для получения фармацевтических средств
PA8855501A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
CR11780A (es) Nuevo proceso para la sintesis de ivabradina y sales de adicion resultantes con un acido farmaceuticamente aceptable (solicitud divisonal)
MX2013007104A (es) Derivados de biciclo[3,2,1]octilamida y sus usos.
EA201190125A1 (ru) Таблетки для комбинированной терапии
BRPI0707704A8 (pt) derivados de antranilamida / 2-amino-heteroareno carboxamida
UA110207C2 (xx) ФАРМАЦЕВТИЧНА ТАБЛЕТКА, ЯКА МІСТИТЬ 1-(β-D-ГЛЮКОПІРАНОЗИЛ)-4-МЕТИЛ-3-$5-(4-ФТОРФЕНІЛ)-2-ТІЄНІЛМЕТИЛ]БЕНЗОЛ ЯК ІНГІБІТОР НАТРІЙЗАЛЕЖНОГО ПЕРЕНОСНИКА ГЛЮКОЗИ (НЗПГ)
CL2009001414A1 (es) Procedimiento de sintesis de 7,8-dimetoxi-1,3-dihidro-2h-3-benzazepin-2-ona sin aislacion de compuestos intermediarios; util para la sintesis de ivabradina.
MX2009011149A (es) Ligandos de receptor de vainilloide novedosos y el uso de los mismos para la produccion de sustancias farmaceuticas.
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
CL2007003875A1 (es) Compuestos derivados de amidas del acido 3-amino tetrahidrofurano-3-carboxilico; procedimiento de preparacion de dichos compuestos.
CL2010000253A1 (es) Procedimiento de preparacion de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable; y uno de los compuestos intermediarios considerados.
EA201000397A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA200701178A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
MX2009004628A (es) Sal de alisquireno con acido orotico.
EA201301136A2 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
EA200701177A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их